DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $69.34, for a total value of $416,040.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kevin R. Sayer also recently made the following trade(s):

  • On Friday, August 11th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The shares were sold at an average price of $69.77, for a total value of $418,620.00.
  • On Wednesday, July 12th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The shares were sold at an average price of $71.86, for a total value of $431,160.00.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 69.99 on Friday. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $94.79. The stock’s 50 day moving average price is $72.62 and its 200-day moving average price is $73.86. The firm’s market cap is $6.06 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.24) EPS. On average, equities research analysts anticipate that DexCom, Inc. will post ($0.78) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/24/kevin-r-sayer-sells-6000-shares-of-dexcom-inc-dxcm-stock.html.

Several brokerages have recently issued reports on DXCM. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Canaccord Genuity reiterated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Tuesday, August 22nd. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Barclays PLC began coverage on DexCom in a research note on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price objective on the stock. Finally, Cowen and Company reiterated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Friday, July 14th. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $86.87.

Large investors have recently bought and sold shares of the business. Advisor Group Inc. boosted its position in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new position in DexCom in the 1st quarter valued at about $164,000. Brighton Jones LLC acquired a new stake in shares of DexCom in the 1st quarter valued at about $204,000. IFP Advisors Inc raised its stake in shares of DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 568 shares in the last quarter. Finally, Independent Portfolio Consultants Inc. raised its stake in shares of DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after purchasing an additional 9 shares in the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.